Table 2.
Patient, Disease and Transplant Characteristics
| Variables | Number (%) |
|---|---|
| Total number | 803 |
| Sex, male | 430 (54%) |
| Age, years | |
| ≤ 10 | 392 (49%) |
| 11 – 20 | 180 (22%) |
| 21 – 30 | 86 (11%) |
| 31 – 40 | 69 (9%) |
| 41 – 50 | 55 (7%) |
| 51 – 62 | 21 (3%) |
| Recipient cytomegalovirus serostatus | |
| Seropositive | 421 (52%) |
| Seronegative | 374 (47%) |
| Not reported | 8 (1%) |
| Disease | |
| Acute lymphoblastic leukemia | 383 (48%) |
| Acute myeloid leukemia | 299 (37%) |
| Chronic myeloid leukemia | 45 (6%) |
| Myelodysplastic syndrome | 76 (9%) |
| Disease status at transplantation | |
| Acute leukemia | |
| 1st complete remission | 247 (31%) |
| 2nd complete remission | 316 (39%) |
| Relapse | 119 (15%) |
| Myelodysplastic syndrome | |
| Refractory anemia | 6 (<1%) |
| Refractory anemia with excess blasts/transformed | 70 (9%) |
| Chronic myeloid leukemia | |
| 1st chronic phase | 23 (3%) |
| 2nd chronic phase / accelerated phase | 5 (<1%) |
| Blast phase | 17 (2%) |
| Conditioning regimen | |
| Total body irradiation + cyclophosphamide ± other | 396 (49%) |
| Total body irradiation + other agents | 54 (7%) |
| Busulfan + cyclophosphamide ± other | 203 (25%) |
| Busulfan + thiotepa ± other | 88 (11%) |
| Busulfan + melphalan ± other | 62/ (8%) |
| Graft-versus-host disease prophylaxis | |
| Cyclosporine + steroid | 649 (81%) |
| Cyclosporine + methotrexate ± steroid | 132 (16%) |
| Other agents | 22 (3%) |